What is HC Wainwright’s Estimate for TARA FY2030 Earnings?

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at HC Wainwright issued their FY2030 earnings per share estimates for Protara Therapeutics in a report released on Wednesday, March 11th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.09) for the year. HC Wainwright currently has a “Buy” rating and a $23.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Several other analysts have also issued reports on TARA. TD Cowen reiterated a “buy” rating on shares of Protara Therapeutics in a research report on Tuesday. JPMorgan Chase & Co. began coverage on shares of Protara Therapeutics in a research report on Wednesday, March 4th. They set an “overweight” rating and a $27.00 price objective for the company. Piper Sandler started coverage on Protara Therapeutics in a research note on Wednesday, January 7th. They set an “overweight” rating and a $24.00 target price for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Protara Therapeutics Stock Down 5.0%

TARA stock opened at $5.32 on Thursday. The company’s 50-day moving average price is $6.10 and its two-hundred day moving average price is $5.35. The firm has a market cap of $274.67 million, a P/E ratio of -4.03 and a beta of 1.40. Protara Therapeutics has a 12 month low of $2.77 and a 12 month high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last posted its quarterly earnings data on Tuesday, March 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.03).

Hedge Funds Weigh In On Protara Therapeutics

A number of institutional investors have recently added to or reduced their stakes in TARA. ADAR1 Capital Management LLC boosted its position in Protara Therapeutics by 3,127.4% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,136,799 shares of the company’s stock valued at $6,059,000 after buying an additional 1,101,576 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Protara Therapeutics during the fourth quarter worth $5,562,000. Janus Henderson Group PLC increased its holdings in shares of Protara Therapeutics by 21.5% during the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after buying an additional 910,285 shares in the last quarter. Integral Health Asset Management LLC increased its holdings in shares of Protara Therapeutics by 60.7% during the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock worth $11,992,000 after buying an additional 850,000 shares in the last quarter. Finally, Maven Securities LTD bought a new position in shares of Protara Therapeutics in the 4th quarter valued at $4,022,000. 38.13% of the stock is currently owned by institutional investors and hedge funds.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.